[go: up one dir, main page]

MX2021003168A - Anticuerpo anti-ox40, fragmento de union al antigeno del mismo y uso farmaceutico. - Google Patents

Anticuerpo anti-ox40, fragmento de union al antigeno del mismo y uso farmaceutico.

Info

Publication number
MX2021003168A
MX2021003168A MX2021003168A MX2021003168A MX2021003168A MX 2021003168 A MX2021003168 A MX 2021003168A MX 2021003168 A MX2021003168 A MX 2021003168A MX 2021003168 A MX2021003168 A MX 2021003168A MX 2021003168 A MX2021003168 A MX 2021003168A
Authority
MX
Mexico
Prior art keywords
antibody
antigen
binding fragment
pharmaceutical use
provides
Prior art date
Application number
MX2021003168A
Other languages
English (en)
Inventor
Xin Ye
Lianshan Zhang
Jiahua Jiang
Cheng Liao
Zupeng Xu
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2021003168A publication Critical patent/MX2021003168A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G01N33/575—
    • G01N33/5758—
    • G01N33/5759—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona un anticuerpo anti-ox40, un fragmento de unión a antígeno del mismo y uso farmacéutico. Además, la presente solicitud proporciona un anticuerpo quimérico y un anticuerpo humanizado, el anticuerpo quimérico y el anticuerpo humanizado que comprenden una región CDR del anticuerpo anti-OX40 y su fragmento de unión al antígeno, y también proporciona una composición farmacéutica que comprende el anti-OX40. anticuerpo y el fragmento de unión a antígeno del mismo, y el uso del mismo como fármaco para tratar cánceres.
MX2021003168A 2018-09-26 2019-09-25 Anticuerpo anti-ox40, fragmento de union al antigeno del mismo y uso farmaceutico. MX2021003168A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811128669 2018-09-26
CN201811417666 2018-11-26
PCT/CN2019/107787 WO2020063660A1 (zh) 2018-09-26 2019-09-25 抗ox40抗体、其抗原结合片段及其医药用途

Publications (1)

Publication Number Publication Date
MX2021003168A true MX2021003168A (es) 2021-05-14

Family

ID=69952440

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003168A MX2021003168A (es) 2018-09-26 2019-09-25 Anticuerpo anti-ox40, fragmento de union al antigeno del mismo y uso farmaceutico.

Country Status (11)

Country Link
US (1) US12227583B2 (es)
EP (1) EP3858857A1 (es)
JP (1) JP2022502417A (es)
KR (1) KR20210069058A (es)
CN (1) CN112513088B (es)
AU (1) AU2019347934A1 (es)
BR (1) BR112021005169A2 (es)
CA (1) CA3113541A1 (es)
MX (1) MX2021003168A (es)
TW (1) TW202035455A (es)
WO (1) WO2020063660A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114106173A (zh) * 2020-08-26 2022-03-01 上海泰槿生物技术有限公司 抗ox40抗体、其药物组合物及应用
CN114106174A (zh) * 2020-08-27 2022-03-01 苏州景涞医疗科技有限公司 低毒性抗ox40抗体、其药物组合物及应用
CN114515335A (zh) * 2020-11-19 2022-05-20 百奥泰生物制药股份有限公司 抗ox40抗体在治疗肿瘤或癌症中的应用
CN120476146A (zh) * 2022-12-30 2025-08-12 甘李药业股份有限公司 抗ox40抗体及其应用
CN118667023B (zh) * 2024-07-16 2025-07-15 上海生物制品研究所有限责任公司 一种抗ox40抗体及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2010518873A (ja) * 2007-02-27 2010-06-03 ジェネンテック， インコーポレイテッド アンタゴニスト抗ｏｘ４０抗体および炎症性疾患および自己免疫性疾患の処置におけるその使用
NZ716369A (en) * 2010-08-23 2017-05-26 Univ Texas Anti-ox40 antibodies and methods of using the same
EA036047B1 (ru) 2011-07-11 2020-09-18 Икнос Сайенсиз Са Антитела, которые связываются с ox40, и их применение
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
EP3126394B1 (en) 2014-03-31 2019-10-30 F.Hoffmann-La Roche Ag Anti-ox40 antibodies and methods of use
MA39355B2 (fr) * 2014-03-31 2021-04-30 Genentech Inc Anticorps anti-ox40 et procédés d'utilisation correspondants
CN115109158A (zh) 2015-05-07 2022-09-27 阿吉纳斯公司 抗ox40抗体及其使用方法
DK3303396T5 (da) 2015-05-29 2024-10-07 Bristol Myers Squibb Co Antistoffer mod ox40 og anvendelser deraf
AU2016364891A1 (en) 2015-12-03 2018-06-07 Agenus Inc. Anti-OX40 antibodies and methods of use thereof
US10442866B1 (en) 2019-01-23 2019-10-15 Beijing Mabworks Biotech Co. Ltd Antibodies binding OX40 and uses thereof

Also Published As

Publication number Publication date
US20210355229A1 (en) 2021-11-18
WO2020063660A1 (zh) 2020-04-02
CN112513088A (zh) 2021-03-16
BR112021005169A2 (pt) 2021-06-15
EP3858857A1 (en) 2021-08-04
KR20210069058A (ko) 2021-06-10
AU2019347934A1 (en) 2021-04-08
TW202035455A (zh) 2020-10-01
CN112513088B (zh) 2023-05-16
US12227583B2 (en) 2025-02-18
CA3113541A1 (en) 2020-04-02
JP2022502417A (ja) 2022-01-11

Similar Documents

Publication Publication Date Title
MX2021005396A (es) Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo.
ZA202004701B (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
MX2021003168A (es) Anticuerpo anti-ox40, fragmento de union al antigeno del mismo y uso farmaceutico.
MY208022A (en) Anti-claudin 18.2 antibody and application thereof
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
MX2018008995A (es) Combinacion de un agonista de ox40 y un agonista de 4-1bb para tratar el cancer.
MX2024007724A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
MX2019005438A (es) Dosificacion para tratamiento con anticuerpos bispecificos anti-cd20 / anti-cd3.
MX2021004588A (es) Anticuerpo anti-cldn18.2 y sus usos.
WO2020014473A8 (en) TGFβ1 INHIBITORS AND USE THEREOF
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
MY209791A (en) Anti-cd79b antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
IL278244B2 (en) Antibodies and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates and uses thereof
MX2019015914A (es) Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide.
NZ758300A (en) Human anti-semaphorin 4d antibody
MX2021002531A (es) Anticuerpo anti-cd38, fragmento de union al antigeno y uso farmaceutico.
MX2020002984A (es) Anticuerpos de cd40 agonistas.
ZA202200906B (en) Anti-her2/anti-4-1bb bispecific antibody and use thereof
MX2014010987A (es) Tratamiento de esclerosis multiple con anticuerpo anti-cd19.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
PH12022552741A1 (en) Anti-ox40 antibody and uses thereof
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
IL289842A (en) Human anti-liv1 antibodies for cancer therapy